{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"59.70","value":"-13.0"},{"groupId":"OG001","spread":"33.92","value":"-29.0"},{"groupId":"OG002","spread":"7.16","value":"-7.44"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"vobramitamab duocarmazine 2.0 mg/kg, IV, every 4 weeks","id":"OG000","title":"Part 1: MGC018 2.0 mg (Arm A)"},{"description":"vobramitamab duocarmazine 2.7 mg/kg, IV, every 4 weeks","id":"OG001","title":"Part 1: MGC018 2.7 mg (Arm B)"},{"description":"abiraterone 1000 mg once daily or enzalutamide 160 mg once daily.","id":"OG002","title":"Part 1: Control Arm"},{"description":"vobramitamab duocarmazine 2.7 mg.kg, IV, every 4 weeks","id":"OG003","title":"Part 2"}],"paramType":"MEAN","populationDescription":"All participants with mCRPC who received at least one dose of study treatment and had RECIST-evaluable disease per PCWG3 (Tumor Response Evaluable Population) in Part 1 of the study. Participants in Part 2 of the study did not have mCRPC and are excluded from this analysis.","reportingStatus":"POSTED","timeFrame":"Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.","title":"Part 1: Mean Best Tumor Size Change Over Time","type":"SECONDARY","unitOfMeasure":"percent change from baseline"}